Physician profile
Ronald Mitchell
NPI 1154556736
$1,571.03
in general payments reported to CMS, 2019-2025
10 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.52 · 2020: $119 · 2021: $112 · 2023: $279 · 2024: $660 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234 · Education: $57.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.16 |
| Education | $57.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polynovo North America LLC | $740.27 | 2024-2025 | Novosorb Btm |
| Bayer Healthcare Pharmaceuticals INC. | $218.10 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $123.42 | 2020-2023 | Hetlioz, Fanapt |
| Novo Nordisk INC | $123.23 | 2020-2024 | Ozempic, Rybelsus |
| Amgen INC. | $113.09 | 2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $102.03 | 2019-2024 | Breztri |
| Amarin Pharma, INC. | $74.60 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.70 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $26.53 | 2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.